Business Wire

BYNDER

19.9.2023 12:25:09 CEST | Business Wire | Press release

Share
Bynder Acquires EMRAYS to Revolutionize DAM User Experience With AI-Powered Innovation

Bynder, the market-leading digital asset management (DAM) platform has today announced the acquisition of EMRAYS, a specialist provider of AI search solutions for DAM.

The acquisition further elevates Bynder’s widely recognised user experience and will improve asset findability for Bynder DAM users. It builds on Bynder’s existing investments in AI and reaffirms the company’s commitment to helping customers conquer the complexity and chaos of proliferating content with the most powerful, intuitive, and richly integrated DAM platform.

With these new capabilities, DAM admins can reduce or eliminate the time and effort needed to manage assets, reduce costs associated with management of their DAM, while improving the speed and relevancy associated with the discovery of assets. EMRAYS enables Bynder customers to further benefit from their market leading user experience, building on their market leading user adoption, especially in large enterprise deployments.

EMRAYS was an existing partner whose technology was built specifically for Bynder DAM. The technology is already adopted within a number of customer accounts and is helping these brands to deliver even better content experiences to their customers.

For brands grappling with the challenges of managing content at scale, EMRAYS similarity search, search by image, text in image search, and duplicate finder impacts the heart of their content operations, allowing teams to find, reuse and deliver more relevant content, quicker and more effectively.

Siemens Healthineers use the Bynder DAM platform across 30,000 users, and already benefit from EMRAYS capabilities. André Kögler, Head of Digital Strategy & Tools, Creative Services said: “EMRAYS AI search enables us to find images and content faster, improving efficiency in our processes. In addition, the enhanced organization features help ensure the content in our Bynder DAM is consistent and high quality.”

Bob Hickey, CEO of Bynder, said: “We are excited to be welcoming the EMRAYS team to Bynder. This announcement comes off the back of recent investments in bringing generative AI capabilities to market.

“Marketing teams across the globe continue to be challenged with the need to manage and distribute a growing volume of targeted content. The acquisition of EMRAYS will help our customers automate the management of this. Like many of our recent AI developments, this acquisition is further proof of Bynder’s commitment to continued innovation and market leadership in the DAM category. The combination of product and people will enable us to accelerate our AI roadmap and deliver additional value to our customers faster.”

Cliff Crosbie, CEO and Co-Founder of EMRAYS said: “AI within DAM has become a strategic ally for marketers seeking to streamline content operations and improve customer experiences. The interest and demand we’ve had from customers to implement our AI technology within the Bynder platform has fueled this partnership and subsequent acquisition. The value that customers receive from EMRAYS capabilities already is invaluable, as marketers overcome content creation challenges and achieve greater efficiency.

“We’re excited about this acquisition and look forward to innovating with Bynder on their AI roadmap.”

For more information on Bynder and its AI capabilities, please visit https://www.bynder.com/en/solutions/initiatives/ai-automation/

-ENDS-

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230919301251/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye